We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-9.1%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$377M
AUM Growth
-$101M
Cap. Flow
-$18.7M
Cap. Flow %
-4.96%
Top 10 Hldgs %
50.73%
Holding
91
New
7
Increased
20
Reduced
15
Closed
11

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$5.15M
2
ALEC icon
Alector
ALEC
+$3.01M
3
IDYA icon
IDEAYA Biosciences
IDYA
+$3M
4
KALV
KalVista Pharmaceuticals
KALV
+$2.61M
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.49M

Top Sells

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$10.6M
2
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$10.4M
3
LMNX
Luminex Corp
LMNX
+$5.12M
4
PRQR icon
ProQR Therapeutics
PRQR
+$4.81M
5
TVRD
Tvardi Therapeutics
TVRD
+$4.5M

Sector Composition

Rank Sector Weight
1 Healthcare 91.17%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISEE
26
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$3.51M 0.93%
216,351
+36,400
+20% +$396K
KALV
27
DELISTED
KalVista Pharmaceuticals
KALV
$3.3M 0.88%
189,163
+128,563
+212% +$2.61M
AERI
28
DELISTED
Aerie Pharmaceuticals
AERI
$3.29M 0.87%
289,040
– –
PRDS
29
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$2.98M 0.79%
299,950
-50
-0% -$497
ACET icon
30
Adicet Bio
ACET
$85.6M
$2.95M 0.78%
23,518
– –
RIGL icon
31
Rigel Pharmaceuticals
RIGL
$749M
$2.94M 0.78%
80,900
+56,500
+232% +$2.22M
MRUS
32
DELISTED
Merus
MRUS
$2.9M 0.77%
131,949
-25,892
-16% -$555K
VKTX icon
33
Viking Therapeutics
VKTX
$3.91B
$2.81M 0.75%
447,400
– –
VERO
34
DELISTED
Venus Concept
VERO
$2.79M 0.74%
6,747
-435
-6% -$171K
TPTX
35
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$2.79M 0.74%
41,952
-5,900
-12% -$420K
KDMN
36
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.74M 0.73%
314,561
-80,000
-20% -$456K
MREO
37
Mereo BioPharma
MREO
$48.4M
$2.73M 0.72%
1,126,613
– –
ETNB
38
DELISTED
89bio
ETNB
$2.48M 0.66%
126,652
+10,200
+9% +$186K
PRQR icon
39
ProQR Therapeutics
PRQR
$278M
$2.48M 0.66%
296,383
-735,497
-71% -$4.81M
ALEC icon
40
Alector
ALEC
$165M
$2.45M 0.65%
+107,412
New +$3.01M
KNTE
41
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$2.45M 0.65%
106,453
+52,038
+96% +$1.13M
NTUS
42
DELISTED
Natus Medical Inc
NTUS
$2.4M 0.64%
95,653
– –
ITOS
43
DELISTED
iTeos Therapeutics
ITOS
$2.24M 0.6%
+83,061
New +$2.17M
STIM icon
44
Neuronetics
STIM
$164M
$2.06M 0.55%
313,717
+60,000
+24% +$575K
IPSC icon
45
Century Therapeutics
IPSC
$353M
$2.01M 0.53%
80,000
– –
CBAY
46
DELISTED
Cymabay Therapeutics
CBAY
$1.91M 0.51%
524,286
+13,900
+3% +$54.8K
HOOK
47
DELISTED
HOOKIPA Pharma
HOOK
$1.9M 0.5%
32,212
– –
KURA icon
48
Kura Oncology
KURA
$817M
$1.89M 0.5%
100,829
+17,300
+21% +$326K
MGNX icon
49
MacroGenics
MGNX
$248M
$1.89M 0.5%
+90,000
New +$2.17M
COGT icon
50
Cogent Biosciences
COGT
$7.22B
$1.88M 0.5%
223,554
– –
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return

DAFNA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, DAFNA Capital Management held 91 positions worth $377M, down 21% from $478M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management withdrew a net $18.7M in Q3 2021, closing 11 positions and reducing 15 holdings. Its most notable exit was Theravance Biopharma, an estimated $10.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in Cytokinetics worth $6.25M.

  • DAFNA Capital Management's largest Q3 2021 buy was Cytokinetics: 175,000 shares worth $6.25M.
  • DAFNA Capital Management added most to IDEAYA Biosciences in Q3 2021, an estimated $3M increase.
  • DAFNA Capital Management's biggest Q3 2021 reduction was ProQR Therapeutics, cutting an estimated $4.81M.
  • DAFNA Capital Management fully exited Theravance Biopharma in Q3 2021, selling an estimated $10.6M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $377M portfolio in Q3 2021.
  • DAFNA Capital Management opened 7 new positions and closed 11 in Q3 2021.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $377M.

Based on DAFNA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.